Guidance raised to >20% growth; Q2 delivers 24% YoY, margin expands 100 bps
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade A
Met Q1 guidance (22.8% growth); Q2 exceeds prior mid-teens target at 24%; FY27 raise to >20% credible given delivered 24%.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 beat guidance with 24% growth and 100 bps margin expansion; management raised FY27 revenue outlook to >20% on strong international momentum (59% of sales, +34.5% YoY) and 20+ product approvals. Key risk: domestic market (Zuventus) consolidating; clarity on acceleration timeline and OTC/specialty traction needed.
₹2820.5 Cr
Revenue · +24.3% YoY₹325.1 Cr
Reported PAT · +29.3% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Earnings quality
What changed since the last call
Revenue growth guidance raised
UpgradePrior mid-teens (10–15%), now >20% for FY27. Q2 delivered 24% YoY, validating confidence in H2 continuation.
EBITDA margin expansion trajectory
UpgradePrior 70–100 bps for year; Q2 alone delivered 100 bps, putting FY27 outlook at upper end (75–100 bps). H1 margin at 20%, 80 bps expansion.
Domestic growth outlook moderated
NeutralQ2 domestic +12% YoY vs +24% overall. Mgmt attributes to Zuventus stabilization post-exits; expects H2 in line with IPM growth, not acceleration.
Net debt increase from prior call
NeutralSept net debt ₹1,317 Cr vs Mar ₹1,054 Cr. Mgmt frames as acquisition-related (Canada, Genova, U.K.); FY28 net cash target maintained.
The Q&A
Analysts pressed on Zuventus growth timeline, domestic OTC scale, ARV/lenacapavir concentration, and capex/OpEx headwinds. Management held firm: Zuventus stabilizing, OTC early-stage (single-digit today), ARV <10% of international, R&D 4% in line. Tone measured; no evasion, though some hesitation on quantified forecasts (e.g., OTC size timeline: 'won't break it out right now').
Europe amphotericin B market — Tushar Manudhane, (Institutional)
PartialNot yet breaking out by product; limited competition. Value + margin product, should be strong for Emcure. Trepostinilalso expected to contribute Europe growth.
Domestic growth acceleration timeline — Alankar Garude, (Institutional)
PartialZuventus already growing faster than industry; H2 FY27 expected strong vs prior-year. Poviztra gaining traction month-on-month, but requires patience. No exact timelines.
International product concentration — Alankar Garude, (Institutional)
AnsweredWell-diversified across Europe, Canada, ROW; complex injectables leading. Amphotericin B <10% of intl. New launches will add to portfolio breadth.
Raw material & cost headwinds — Alankar Garude, (Institutional)
PartialSome imported raw-material and freight-cost impact; benefited from currency. H2 outlook 'relatively comfortable' but rising input costs acknowledged.
R&D spend & guidance — Foramh Parekh, (Institutional)
AnsweredQ2 R&D 4% of revenue; will remain within 4–5% bracket for full year. Investment tilted to international markets.
Amphotericin B manufacturing sites & inspections — Kartick Bane, Bajaj Life
Answered2 sites for amphotericin B; UK & Europe approvals secured. Regulatory audits recently closed. Next 18–24 months, facilities should be free of restrictions.
Semaglutiide supply availability Canada — Alankar Garude, (Institutional)
AnsweredSupply likely within next few months. Will launch when supply secured; expect Q4 FY27 or later per mgmt.
ARV/lenacapavir market opportunity & margin — Foramh Parekh, (Institutional)
AnsweredARV margins lower than overall corporate; growth solid. Lenacapavir important for ARV but not over-concentrated; <10% of intl at most. Tender visibility strong, medium-term expansion confident.
OTC/consumer health scaling & hospital contribution — Tushar Manudhane, (Institutional)
PartialOTC scaling; MR count stable ~4,100–4,200 (no near-term additions). Hospital portfolio (e.g., Orofer XT, Pause, Metpure, Asomex) doing well; hospital side single-digit but growing. Not breaking out exact numbers yet.
In-licensed product contribution India — Alok Dalal, (Unknown firm)
PartialIn-licensed products ~high-teens % of India sales. Biosimilars <10% India, lower international. Not breaking out separately yet; will discuss when reaches meaningful scale.
Guidance
FY27 revenue growth >20% (raised from low-to-mid-teens)
HighQ2 delivered 24% YoY; H1 at +23.6%. Management confident in H2 momentum continuation; domestic stabilization + international approvals backing view.
Domestic growth in-line with IPM (single-digit to low-double-digit), full-year vs prior-year
MediumQ2 domestic +12% YoY post-Zuventus exits. Management expects H2 strong vs prior year but not acceleration; OTC & specialty scaling gradual.
EBITDA margin expansion 75–100 bps for FY27 (expect upper end)
HighQ2 delivered 100 bps; H1 margin 20% with 80 bps expansion. Operating leverage + mix continuing; raw material headwinds muted so far.
PAT margin stability; 11.5% delivered Q2 (vs 11.05% prior year)
MediumEffective tax rate 27%; finance cost rising due to acquisition debt, but EBITDA growth offsetting. Expect sustained mid-11% margins.
Capex related to amphotericin B site diversification; 18–24 months to unrestricted capacity
Medium2 manufacturing sites; U.K. & Europe approvals secured; audits cleared. No quantified capex guidance but mgmt flags ongoing investment in compliance & capacity.
Risks the call surfaced
Domestic market headwinds
MediumDomestic +12% YoY (vs 24% overall). Zuventus ~25% of revenues; post-exodus stabilization expected but not acceleration. OTC/specialty traction early-stage.
International tender business margin pressure
MediumARV ~50% of ROW; margins lower than corporate avg. Lenacapavir opportunity strong order book but emerging-market tender competition & pricing pressure ongoing. No quantified margin guidance for intl segments.
Raw material & freight cost inflation
MediumImported APIs & freight costs rising. Q2 benefited from favorable forex, masking some headwinds. H2 'relatively comfortable' per mgmt but no hedge quantified.
Geopolitical & macro volatility
LowIran tensions, Ukraine situation could impact oil/freight. Mgmt acknowledges uncertainty but sees near-term as 'looks good.' No specific hedging disclosed.
Regulatory & manufacturing capacity risks
Low2 amphotericin B sites; audits recently closed. U.K. acquisitions undergoing integration; approvals pending. 18–24 months to full operational unrestricted capacity.
Management
Score 7/10. Clear on financials & strategy. Transparent on Zuventus challenges & domestic headwinds. Defensive on OTC/semaglutiide timelines ('won't break it out right now'). Candid on macro risks; measured tone quarter-by-quarter. Met Q1 guidance (22.8% growth). Q2 surpassed (24%). H1 PAT +33% YoY, EBITDA margin 20%. Acquisitions (Canada, Genova, U.K.) on track; integration visible. R&D 4% on guidance.
1 · H2 FY27
Domestic growth acceleration post-Zuventus stabilization, new formulation launches
2 · Next 6–12 months
Amphotericin B, trepostinilII, lenacapavir, bevacizumab approvals & ramp across ROW
3 · FY28
Semaglutiide supply from partner (Quebec), target net cash conversion
Key risk: domestic market (Zuventus) consolidating; clarity on acceleration timeline and OTC/specialty traction needed.
24% growth & guidance raised — but the stock is priced for perfection at overbought levels
Guidance raised to >20% growth on a delivered 24% beat, international momentum, and 100 bps margin expansion. The real story: domestic growth slowed to 12% as Zuventus stabilizes, and the stock (RSI 76.4, +69% YTD) has priced all of this in hard.
The quarter at a glance
₹2,820.5 Cr
+24.3% YoY, +9.3% QoQ
₹325.1 Cr
+29.3% YoY, +11.1% QoQ
20.4%
+100 bps YoY, +70 bps QoQ
11.5%
+45 bps YoY
Emcure delivered a clean quarter: revenue and profit beat prior guidance, margins expanded 100 basis points, and management raised full-year guidance from low-to-mid-teens to exceed 20%. The profit is organic — no one-time gains, no MTM cushions. But the headline masks a critical divergence: international revenue surged 34.5% YoY, while domestic growth slowed to 12% as Zuventus, the domestic-focused acquisition from Q4 FY26, stabilized after a management exodus and customer exodus. International is now 59% of sales and firing; domestic is struggling. For equity holders, the question is whether >20% growth can be sustained for another two quarters when one of the two engines is clearly at reduced throttle.
Where the growth came from — and where it didn't
The decomposition exposes the vulnerability. International revenue — driven by 20+ product approvals in Q2 (liposomal amphotericin B in Brazil & Mexico, bevacizumab wet-AMD in India, trepostinilII in Europe) — is on fire. Europe grew 36% YoY; Canada +24%; rest of world +41%. But international alone is 59% of sales; if it slows, the blended growth falls fast. Domestic, at 12% YoY, is held back by Zuventus consolidation. Management flagged Zuventus as roughly 25% of total revenues; post-exodus stabilization is keeping it to low-double-digit growth, in-line with the broader IPM (India pharma market) expansion rate. The narrative from the call was 'H2 expected strong vs. prior year' — but that's a low bar (comparison to a weak year) and no acceleration is promised.
What changed on this call
Revenue guidance raised: FY27 now >20% (vs prior low-to-mid-teens, i.e., 10–15%). Q2 delivered 24% YoY; H1 at +23.6%. Management confident H2 continuation is credible if international approvals ramp as planned.
EBITDA margin guidance upside: Prior 70–100 bps expansion for FY27; Q2 alone delivered 100 bps. Management now expects 'upper end' (likely 75–100 bps), and H1 margin is 20% (+80 bps YoY). Mix, leverage, and productivity all contributing.
Domestic headwind explicit: Domestic +12% YoY (vs 24% blended). Zuventus stabilizing, not accelerating. Management expects H2 'in-line with IPM,' not a step-change. This is a moderately bullish framing but not a growth driver.
Net debt up ₹263 Cr YTD: Acquisition-driven (Canada finalization ₹551 Cr, Genova minority, U.K. product portfolio). FY28 net-cash target maintained; not a core operational risk, but capex and integration visibility are key.
Claims management made on the call — and what holds up
Revenue 24% YoY to ₹2,820 Cr
SupportedDelivered ₹2,820.5 Cr, +24.3% YoY
PAT 29% YoY to ₹325 Cr
SupportedDelivered ₹325.1 Cr, +29.3% YoY
EBITDA margin expansion ~100 bps to 20.4%
SupportedEBITDA ₹575 Cr, margin 20.4%, +100 bps YoY
International revenue +34.5%, 59% of total
Supported₹1,665 Cr Int'l, +34.5%, 59% of ₹2,820.5 Cr
20+ product approvals in Q2
SupportedCited: amphotericin B (Brazil, Mexico), bevacizumab (India), trepostinilII (Europe), +others
FY27 guidance >20% (raised from mid-teens)
SupportedPrior 10–15%, now >20% on delivered 24%
The bull case
International scale is real and accelerating. 59% of revenue growing at 34.5% YoY with no single-product concentration (ARV is 20% guidance.
Margin expansion is broad-based. 100 bps in Q2 came from business mix (international higher-margin), productivity, and operating leverage. Gross margin improved 110 bps YoY despite rising imported raw-material and freight costs — the offset came from favorable forex and volume lift. EBITDA margin at 20.4% puts FY27 'upper end' of 75–100 bps expansion within reach; H1 is already +80 bps.
Execution credibility is high. Met Q1 guidance (22.8% growth, reaffirmed low-to-mid-teens). Q2 surpassed at 24%. PAT beat at +29.3% YoY showing not just revenue beat but margin beat too. Canada acquisition (₹551 Cr finalization in H1), Genova minority, U.K. portfolio integration on track. R&D at 4% of revenue, on guidance. No capital shocks or surprises.
The bear case
Domestic growth is a structural brake. Zuventus is ~25% of revenues and post-exodus stabilization suggests it will contribute low-single-digit to low-double-digit growth, in-line with IPM. That's a drag on blended growth. If Zuventus continues to hover at 10% or declines, domestic could slip to mid-single digits in H2, pulling blended growth below the >20% target. The company gave no quantified domestic target — a sign of caution.
Emerging-market tender pressure is structural and unresolved. ARV is 50% of rest-of-world revenue; margins are lower than corporate average. Lenacapavir is the emerging-market 'next-gen' growth driver, but tender competition is intense and pricing is eroding. Management withheld specific lenacapavir revenue guidance and margin profile — a red flag for caution. If ROW tender pricing compresses further, overall international margin resilience is tested; the company's >20% growth could come with margin headwinds.
Raw material and geopolitical headwinds are rising. Imported APIs and freight costs are climbing. Q2 benefited from favorable forex, which masked input-cost inflation; management flagged H2 as 'relatively comfortable' but acknowledged 'rising input costs.' Geopolitical risks (Iran tensions escalation, Ukraine) could spike oil/freight costs sharply. No hedging strategy disclosed; upside CPI risk is unmanaged.
How the street is positioned — and what it means
Price & technicals — overbought and near ATH. Emcure closed at ₹2,212.8, just −2.36% below its all-time high of ₹2,266.4. The stock has rallied 69% off its 52-week low (₹1,306.5) and trades well above its 20-day moving average (₹1,894.14), 50-day (₹1,912.68), and 200-day (₹1,737.24). RSI at 76.4 signals overbought conditions — a yellow flag for profit-taking and exhaustion. Volume is increasing, which suggests conviction, but also suggests liquidity for sellers to exit.
Institutional ownership — rising, but not a stampede. FII ownership increased to 4.88% (up 153 bps QoQ from 3.35%); DII to 8.46% (up 236 bps from 6.10%). Institutions are adding, but the pace is incremental, not aggressive. Promoter ownership is steady at 77.83% (−4 bps QoQ), suggesting no planned capital raising or dilution.
Insider / block deal activity — a contrarian red flag. BC Investments (likely a PE fund or hedge fund) sold 9.7 million shares @ ₹1,817 per share in recent block deals. Institutional funds (HSBC MF, Axis MF, Goldman Sachs, Morgan Stanley, HDFC Life, BNP Paribas) then bought at that same ₹1,817 price. The stock is now ₹2,212.8 — a +22% rally from those transaction prices. BC's decision to trim (and the stock's subsequent rally) is a classic contrarian signal: insiders selling into strong momentum, especially near ATH, often precede corrections. The fact that institutions stepped in and are now up 22% does not negate the yellow flag — it suggests some buying pressure remains, but profit-taking risk is elevated.
Reconciliation — the market has priced in all the good news. The fundamental story (guidance raise, 24% growth, margin expansion, international momentum) is reflected in the stock's valuation (likely 35–40x FY27 PAT). At current overbought technicals (RSI 76.4, near ATH, +69% YTD) and insider selling, the risk/reward is asymmetric to the downside. The margin of safety has collapsed. For holders, this is a moment to consider profit-taking. For new buyers, the entry point is not compelling.
Risks ranked by impact on a holder
Domestic growth deceleration / Zuventus stabilization stalls
HighZuventus is 25% of revenues; post-exodus stabilization contributed only 12% growth in Q2 (vs 24% blended). If domestic slows further, blended growth drops below 20% target, and FY27 guidance is missed.
Emerging-market tender pricing compression
MediumARV is 50% of ROW (~15–20% of total). Lenacapavir opportunity is real but emerging-market tender pricing is commoditizing. If margins compress, the >20% growth comes with margin headwinds, not expansion.
Raw material/freight cost inflation + geopolitical shocks
MediumQ2 benefited from favorable forex; H2 risks rising input costs and oil volatility (Iran/Ukraine scenarios). Gross margin 110 bps improvement could reverse. No hedging disclosed.
Manufacturing/regulatory delays (amphotericin B, U.K. portfolio)
Medium2 amphotericin B sites; 18–24 months to full unrestricted capacity. Recent audits cleared, but regulatory dependencies remain. Delays would push new-product ramps into FY28, missing FY27 growth momentum.
Valuation drawdown on technical reversal
MediumStock is overbought (RSI 76.4, near ATH, +69% YTD). Insider selling, rising technical risk. A 15–20% pullback is possible if H2 guidance is missed or macro headwinds surface.
The debate
What to watch next — three catalysts that resolve the debate
1 · H2 FY27 domestic growth acceleration (Zuventus stabilization into ramp)
Management expects H2 'strong vs. prior year' (low bar, year-on-year comparison). If domestic grows >15% in H2 vs 12% in Q2, it validates the stabilization-to-ramp narrative and supports >20% blended target. If domestic stays at 12% or decelerates, the Zuventus story is stalled, and FY27 misses guidance.
2 · Amphotericin B Europe launch and revenue contribution (next 6–12 months)
One of 20+ Q2 approvals. Europe is a high-margin market; U.K. & Europe approvals already secured. If amphotericin B ramps to ₹50–80 Cr annualized run-rate by Q4 FY27, it validates international growth durability. Manufacturing site audits cleared; timeline is key.
3 · Semaglutiide Canada launch and Poviztra obesity market traction (FY28 signaling)
Semaglutiide supply expected 'next few months' (Q4 FY27+); Poviztra obesity brand 'early-stage' today but a mid-term growth lever. If management guides FY28 growth >15% on these catalysts, it signals confidence in next-phase drivers. If FY28 guidance is muted, core franchises are saturating and growth is cyclical.
The honest read
Q2 was a solid beat: +24.3% revenue, +29.3% profit, +100 bps margin expansion. Management raised FY27 guidance to >20% — a credible move backed by delivered 24% and international momentum. This is NOT a step-change in the franchise; it's a steady, profitable compounder running hard on its international fuel tank. Domestic is stabilizing, not accelerating, and tender margins are under structural pressure.
The stock has priced all of this in: up 69% YTD, near ATH, overbought (RSI 76.4), with insider selling and institutional buying at lower prices followed by a 22% rally. The technical setup is stretched. For holders, the risk/reward at ₹2,212.8 favors taking profits. For new buyers, there is no margin of safety.
The single number to track from here: H2 FY27 domestic revenue growth. If it re-accelerates above 15%, the Zuventus story is working and >20% is achievable. If it stays at 12%, Emcure is international-dependent and macro-sensitive, not the premium compounder the market is pricing. That one number resolves the debate. Until then, hold on strength; do not chase at ₹2,212.
Emcure delivered, raised guidance, and proved execution. The stock has priced it all in, and insiders are trimming near the highs. Profitability is real; sustainability is unproven. Holders: take profits. Buyers: wait for a pullback.
Emcure expects to sustain export momentum—watch for margin trajectory amid higher international mix
The pharma leader enters Q2 with strong Q1 tailwinds: 23% revenue growth, 36% profit jump, and guidance to low-teen FY27 expansion. Street is 83% buy; the test is whether international scaling and the Gennova integration sustain the pace while gross margins face headwinds from higher export mix.
The Setup
Emcure reports Q2 FY27 results on November 3, 2026. The pharma play enters the quarter on the back of an exceptionally strong Q1: consolidated revenue grew 22.8% YoY to ₹2,580 crore, while PAT surged 36.2% to ₹292.5 crore. The headline win was international revenue jumping 34% YoY—signaling genuine export traction—while domestic growth of 10% signals selective domestic market gains amid a highly competitive environment. Street consensus is decisively bullish: 83% of analysts carry buy/strong buy ratings, with a median price target of ₹1,932 (8–26% upside), anchored on expectations of sustained FY27 revenue growth and expanding profit conversion.
~₹2,650–2,700 Cr
On-plan 23–25% YoY growth; Q1 was ₹2,580 Cr at +22.8%
~₹300–320 Cr
Maintaining double-digit profit growth; Q1 was ₹292.5 Cr at +36.2%
~59%
FY27 guidance; Q1 was 58.4% (down 340 bps YoY from 62.4% mix shift to exports)
~70–100 bps
FY27 guidance despite gross margin headwind; operational leverage from scale
What a strong quarter looks like: Revenue growth >24% with export mix holding above 50%, PAT margin improving to 11.5%+ (on operating leverage), and management reiterating FY27 guidance with confidence. What a weak quarter looks like: Revenue growth <22%, export growth slowing below 20%, PAT margin contracting due to competitive pricing or inventory corrections, and any signal of margin pressure in Q3–Q4.
On Track?
Emcure is firmly tracking its full-year FY27 guidance for low to mid-teen revenue growth and 70–100 bps EBITDA margin expansion. Q1's 22.8% revenue growth and 110 bps PAT margin expansion suggest room on both metrics. The company has also confirmed low-to-mid-teen growth for FY27 in its August concall, setting a 12–15% revenue CAGR bar. The swing factor: whether the international business can sustain 30%+ growth (critical to the beat case) or normalizes to 20%+ in Q2 as the base effect from the prior year's softer Q2 FY26 abates. Domestic growth remains the steady-state anchor at ~10%.
Since Last Quarter
Gennova integration in progress. Emcure completed its acquisition of the remaining 12.05% stake in Gennova Biopharmaceuticals (July 21, 2026), making it wholly owned. Gennova is a biotech play in vaccines and oncology; the integration is expected to open new therapeutic vectors and scale biotech revenue. Watch for any production or regulatory delays in the concall.
Merger of subsidiaries approved. On October 12, 2026, Emcure's board approved a Composite Scheme of Amalgamation combining Zuventus Healthcare and Emcutix Biopharmaceuticals into the parent. This is routine consolidation; expect no material impact on Q2 results but may simplify governance and reduce operating costs post-close.
Tax penalty flagged. On October 2, 2026, the Income-Tax Department issued a penalty order of ₹57.7 crore for FY15–21. Emcure flagged this as under legal review. The impact on Q2: likely none (it is a penalty, not a provision change in this quarter). Monitor for any P&L charge or liability movement in the balance sheet.
Board changes. Berjis Desai retired as Chairman and Non-Executive, Non-Independent Director post-AGM on September 21, 2026, and has been replaced. This is governance routine; no operational impact.
FDA inspection closed—EIR received. In August 2026, Emcure received an Establishment Inspection Report (EIR) from the USFDA for its Sanand formulations facility (Ahmedabad). EIR with no warning letters is a clean bill. This supports export growth confidence for Q2 onwards.
1 · Export growth trajectory
Q1 international revenue grew 34% YoY. Management guidance is 'mid-to-high-teen' FY27 growth. Watch whether Q2 export growth holds at 25%+ (accounting for easier base effect from Q2 FY26) or softens. Any slowdown <20% should trigger margin-pressure concerns.
2 · Gross margin defense
FY27 guidance is ~59% (vs 62% in FY26). Q1 was 58.4%. Q2 result will signal whether the company can hold 59% or if export mix and competitive pressure push it further down. EBITDA margin expansion depends on operational leverage; if gross margin deteriorates further, watch for flat or negative EBITDA margin movement.
3 · Gennova contribution and integration update
Emcure consolidated Gennova from July 21 onwards. Q2 will show the first 2+ months of consolidated results (Gennova was equity-accounted in Q1). Listen for management commentary on Gennova's revenue contribution, vaccine/oncology pipeline status, and any integration challenges or capex plans.
4 · FY27 guidance reiteration and Q3–Q4 visibility
Management has guided low-to-mid-teen FY27 growth and 70–100 bps EBITDA margin expansion. With Q1 at 22.8% and Q2 on track, the full-year 12–15% guide is achievable only if Q3–Q4 moderates. Ask for clarity on base-effect normalization and growth ramp for H2. Any downward revision on FY27 growth would be a shock.
Emcure enters Q2 with the wind at its back: a 34% export surge in Q1, a successful Gennova full consolidation, a clean USFDA inspection, and a bullish Street of 83% buy ratings. The company is tracking its low-to-mid-teen FY27 growth guidance, and profit conversion has been exemplary. The question for result day is margin—whether the company can hold the 59% gross margin guidance and expand EBITDA margins by 70–100 bps despite the headwind from higher international mix. Domestic growth remains key to the bull case; any pickup there would offset export margin pressure. Watch for realistic FY27 guidance, Gennova integration color, and management's tone on H2 growth sustainability.
Emcure Q2 FY27: consolidated PAT +29% YoY to ₹325 Cr, margin expands, beats guidance
PAT +29.3% YoY · revenue +24.3% · margins expanding
₹2,820.47 Cr
+24.3% YoY
₹325.07 Cr
+29.3% YoY
11.51%
+0.4pp YoY
₹17.16
Emcure's consolidated Q2 FY27 print was strong on a YoY basis: revenue rose 24.3% to ₹2,820.5 Cr (₹2,269.8 Cr a year ago) and PAT rose 29.3% to ₹325.1 Cr (₹251.4 Cr), with EPS at ₹17.16 against ₹12.85. Sequentially, revenue was up 9.3% and PAT up 11.1% over Q1 FY27 (₹2,580.4 Cr revenue, ₹292.5 Cr PAT), but that QoQ move is secondary to the YoY trend, which marks a second straight quarter of 20%+ growth well above management's standing full-year guidance. No exceptional items hit the quarter, and the year-ago quarter was equally clean, so the growth is not flattered by base effects.
Q2 FY-2027 vs prior quarters
The expansion was broad-based rather than single-engine: international sales grew 34.5% YoY to ₹1,665.2 Cr (59% of revenue), with Europe up 36.0% to ₹604.3 Cr on continued Liposomal Amphotericin B scale-up, Canada up 24.0% to ₹431.2 Cr, and Rest of World up 41.1% to ₹629.7 Cr on ARV and non-ARV portfolio expansion. Domestic sales grew a slower 12.0% YoY to ₹1,155.3 Cr, led by Women's Health, Cardio-Metabolics and the CNS range. On margins, EBITDA margin expanded 103 bps YoY to 20.4% and PAT margin 45 bps to 11.5%, which management attributes to productivity gains and operating leverage; R&D spend of ₹111.0 Cr was about 4% of revenue, at the low end of the 4-5% band management has guided to.
The stock went into the print at ₹1,978.2, up 2.3% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
No exceptional items this quarter — clean print versus a ₹3.5 Cr one-off legal settlement booked in H1 FY26
FY27 low-to-mid-teen revenue growth (reaffirmed despite Q1's 22.8% beat). EBITDA margin expansion 70–100 basis points (50 bps delivered Q1). R&D expense 4–5% of revenue. Net cash target by FY28-end.
— This quarter: beat
Against management's own prior guidance — low-to-mid-teen FY27 revenue growth and 70-100 bps EBITDA margin expansion, reaffirmed at the Q1 concall despite Q1's 22.8% beat — this quarter is another clear beat: H1 FY27 revenue is up 23.6% YoY, roughly double the top end of the full-year revenue guide, and H1 EBITDA margin expansion of 79 bps YoY is already most of the way to the full-year target with two quarters left. Full-year Street consensus (per forecast aggregators) pegs FY27 revenue growth at a much lower ~13.3%, implying the market is still pricing a sharp H2 deceleration that the current run-rate does not show; no quarter-specific Street preview for Q2 was found to confirm a beat/miss against estimates. The quarter also carried several corporate-structure moves: Gennova Biopharmaceuticals became a wholly owned subsidiary on 21 July 2026 (its minority stake bought out), Gennova separately divested its mRNA business undertaking via slump sale for ₹139.5 Mn on 10 July 2026, and the board approved a composite amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals into Emcure on 12 October 2026, pending NCLT approval. Separately, the company disclosed a ₹57.7 Cr income-tax penalty on 2 October 2026 that does not appear as an exceptional item in this statement — its provisioning treatment bears watching next quarter.
W1
Whether FY27 revenue growth converges toward management's reaffirmed low-to-mid-teens full-year guide from the current 23.6% H1 YoY run-rate, or whether guidance gets revised up
W2
EBITDA margin trajectory toward/beyond the guided 70-100 bps FY27 expansion — H1 already at +79 bps YoY to 20.0%
W3
Provisioning/contest status of the ₹57.7 Cr income-tax penalty disclosed 2-Oct-26, not reflected as an exceptional item in this filing
Legible, typeset statement; no exceptional items in the Q2 FY27 or Q2 FY26 quarterly columns (a ₹3.5 Mn one-off legal settlement sits only in the H1/full-year columns, outside this quarterly comparison). NCI turned slightly negative (-₹4.97 Mn) after Gennova became a wholly owned subsidiary on 21-Jul-26. Consolidated is primary; standalone PAT ₹248.4 Cr is directionally consistent (standalone revenue +32.3% YoY, faster than consolidated, reflecting intercompany/export routing differences).